Introduction and methods: We compared the most frequent indications for the fi rst autoHSCT and alloHSCT performed in the Czech Republic in years [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . This period was splitted into three: 1995-1999, 2000-2004 and 2005-2009 . The disease status at transplant, overall survival (OS) and the reason of death were compared for each diagnosis and HSCT type. Promise 2 was used as the source of data. Results: In the study period, 3627 fi rst autoHSCT and 1743 fi rst alloHSCT were registered. The most frequent indications for autoHSCT were lymphomas and MM which represent 77% of the autoHSCT. The autoHSCT were performed also for solid tumours (11,6%), AML (4,1%), CLL (2,6%), ALL (1,5%) and other less frequent diagnostic groups. The main indications for alloHSCT were: AML (28,5%), CML (18,2%), MDS/MPN (16,4%), ALL (16%), CLL (5,8%), BM failure (5,6%) and other. Total 497 alloSCT were performed for AML, there was a shift towards HSCT in 1st complete remission (CR) in more recent periods (32.3 vs 57.5 vs 65.3%), there was similar ratio of death due to relapse and TRM, with surprisingly higher death rate in 2000-2004 period compared to the others. Total 318 alloHSCT were performed for CML, there was a shift towards HSCT in 1st (chronic phase) CP in more recent periods (82.7 vs 71.6 vs 53.6%). The main cause of death was the TRM (86 pts, 65%). Total 1247 autoHSCT were performed for NHL, there was a shift towards SCT in 1st CR in more recent periods (25.2 vs 33.75 vs 36.8%). The main cause of death was relapse or progression (221 pts, 63%). Total 1171 autoHSCT were performed for MM, there was a shift towards HSCT in 1st CR in more recent periods (1 vs 3 vs 9%), other indications were the same. The main cause of death was relapse or progression (290 pts,73%). Overall survival according to the time of transplantation One of the responsibilities of the Agence de la biomédecine is to evaluate centres performing allogeneic haematopoïetic stem cell transplantation (HSCT) in France. According to this mission, and with the support of the Société Française de Greffe de Moelle et de Thérapie Cellulaire, a study aimed at detecting centres with adjusted mortality rates signifi cantly different from the national mortality rate. Results of such studies can secondarily be investigated in order to improve quality of care. Two end points were chosen: overall mortality and transplant related mortality (TRM) at one year. Patients with fi rst allogeneic HSCT performed between 2001 January 1st and 2006 December 31st were included. Centres performing less than 12 allogeneic HSCT during this period were excluded. Patients with haploidentical or syngeneic transplant or with a diagnosis representing less than 1% of the cohort were excluded. Adult and pediatric transplants were studied separately. The statistical method used (1) consists on plotting, under the null hypothesis that centres are not different, the French national one-year mortality rate with its 99% confi dence interval, against the centre size (i.e. number of allogeneic HSCT performed). This is called a funnel plot since the confi dence interval shrinks as centre size grows. Relevant prognostic factors are determined using survival models with univariate and multivariate analyses performed on the data of all centres together. From the best model found, the expected number of deaths at one year in each centre is derived. Then the adjusted one-year mortality rate of each centre is computed as the national one-year mortality rate weighted by the ratio of the observed and expected numbers of deaths at one year in the centre, and plotted as a point on the funnel plot. Centres with a point out of the confi dence interval have a one-year mortality rate signifi cantly higher or lower than the national rate. Results showed a good homogeneity among centres. Six centres had an adjusted one-year overall mortality or TRM rate signifi cantly different from the national rate. Further analyses will be done to determine reasons for differences and to improve the management of competing risks. 
